Effect of curcumin on the cell surface markers CD44 and CD24 in breast cancer

Calaf,Gloria M.; Ponce-Cusi,Richard; Abarca-Quinones,Jorge

doi:10.3892/or.2018.6386

Effect of curcumin on the cell surface markers CD44 and CD24 in breast cancer

Authors:
- Gloria M. Calaf
- Richard Ponce-Cusi
- Jorge Abarca-Quinones
View Affiliations

Affiliations: Instituto de Alta Investigación, Universidad de Tarapacá, Arica 8097877, Chile, School of Medicine, Saint-Luc Hospital, IMAG Unit (IREC), University of Louvain, Brussels 1200, Belgium
Published online on: April 20, 2018 https://doi.org/10.3892/or.2018.6386
Pages: 2741-2748

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human breast cell lines are often characterized based on the expression of the cell surface markers CD44 and CD24. CD44 is a type I transmembrane glycoprotein that regulates cell adhesion and cell-cell, as well as cell-extracellular matrix interactions. CD24 is expressed in benign and malignant solid tumors and is also involved in cell adhesion and metastasis. The aim of the present study was to investigate the effects of curcumin on the surface expression of CD44 and CD24 in breast epithelial cell lines. An established breast cancer model derived from the MCF-10F cell line was used. The results revealed that curcumin decreased CD44 and CD24 gene and protein expression levels in MCF-10F (normal), Alpha5 (premalignant) and Tumor2 (malignant) cell lines compared with the levels in their counterpart control cells. Flow cytometry revealed that the CD44+/CD24+ cell subpopulation was greater than the CD44+/CD24- subpopulation in these three cell lines. Curcumin increased CD44+/CD24+ to a greater extent and decreased CD44+/CD24- subpopulations in the normal MCF-10F and the pre-tumorigenic Alpha5 cells, but had no significant effect on Tumor2 cells compared with the corresponding control cells. Conversely, curcumin increased CD44 and decreased CD24 gene expression in MCF-7 breast cancer cells, and decreased CD44 gene expression in MDA-MB-231 cell line, while CD24 was not present in these cells. Curcumin did not alter the CD44+/CD24+ or CD44+/CD24- subpopulations in the MCF-7 cell line. However, it increased CD44+/CD24+ and decreased CD44+/CD24- subpopulations in MDA-MB-231 cells. In breast cancer specimens from patients, normal tissues were negative for CD44 and CD24 expression, while benign lesions were positive for both markers, and malignant tissues were found to be negative for CD44 and positive for CD24 in most cases. In conclusion, these results indicated that curcumin may be used to improve the proportion of CD44+/CD24+ cells and decrease the proportion of CD44+/CD24- cells. Therefore, it may be suggested that curcumin decreased cancerous types of breast cells.

View Figures

View References

1	Han JS and Crowe DL: Tumor initiating cancer stem cells from human breast cancer cell lines. Int J Oncol. 34:1449–1453. 2009.PubMed/NCBI
2	Gudjonsson T, Villadsen R, Nielsen HL, Rønnov-Jessen L, Bissell MJ and Petersen OW: Isolation, immortalization, and characterization of a human breast epithelial cell line with stem cell properties. Genes Dev. 16:693–706. 2002. View Article : Google Scholar : PubMed/NCBI
3	Vesuna F, Lisok A, Kimble B and Raman V: Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression. Neoplasia. 11:1318–1328. 2009. View Article : Google Scholar : PubMed/NCBI
4	Fang X, Zheng P, Tang J and Liu Y: CD24: from A to Z. Cell Mol Immunol. 7:100–103. 2010. View Article : Google Scholar : PubMed/NCBI
5	Sleeman KE, Kendrick H, Ashworth A, Isacke CM and Smalley MJ: CD24 staining of mouse mammary gland cells defines luminal epithelial, myoepithelial/basal and non-epithelial cells. Breast Cancer Res. 8:R72006. View Article : Google Scholar : PubMed/NCBI
6	Fogel M, Friederichs J, Zeller Y, Husar M, Smirnov A, Roitman L, Altevogt P and Sthoeger ZM: CD24 is a marker for human breast carcinoma. Cancer Lett. 143:87–94. 1999. View Article : Google Scholar : PubMed/NCBI
7	Kristiansen G, Winzer KJ, Mayordomo E, Bellach J, Schlüns K, Denkert C, Dahl E, Pilarsky C, Altevogt P, Guski H, et al: CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res. 9:4906–4913. 2003.PubMed/NCBI
8	Lim SC: CD24 and human carcinoma: Tumor biological aspects. Biomed Pharmacother. 59 Suppl 2:S351–S354. 2005. View Article : Google Scholar : PubMed/NCBI
9	Jaggupilli A and Elkord E: Significance of CD44 and CD24 as cancer stem cell markers: An enduring ambiguity. Clin Dev Immunol. 2012:7080362012. View Article : Google Scholar : PubMed/NCBI
10	Ponta H, Sherman L and Herrlich PA: CD44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 4:33–45. 2003. View Article : Google Scholar : PubMed/NCBI
11	Orian-Rousseau V: CD44, a therapeutic target for metastasising tumours. Eur J Cancer. 46:1271–1277. 2010. View Article : Google Scholar : PubMed/NCBI
12	Hanahan D and Weinberg RA: The hallmarks of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
13	Marhaba R and Zöller M: CD44 in cancer progression: Adhesion, migration and growth regulation. J Mol Histol. 35:211–231. 2004. View Article : Google Scholar : PubMed/NCBI
14	Günthert U, Hofmann M, Rudy W, Reber S, Zöller M, Haussmann I, Matzku S, Wenzel A, Ponta H and Herrlich P: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 65:13–24. 1991. View Article : Google Scholar : PubMed/NCBI
15	Kristiansen G, Sammar M and Altevogt P: Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol. 35:255–262. 2004. View Article : Google Scholar : PubMed/NCBI
16	Lee JH, Kim SH, Lee ES and Kim YS: CD24 overexpression in cancer development and progression: A meta-analysis. Oncol Rep. 22:1149–1156. 2009.PubMed/NCBI
17	Kristiansen G, Machado E, Bretz N, Rupp C, Winzer KJ, König AK, Moldenhauer G, Marmé F, Costa J and Altevogt P: Molecular and clinical dissection of CD24 antibody specificity by a comprehensive comparative analysis. Lab Invest. 90:1102–1116. 2010. View Article : Google Scholar : PubMed/NCBI
18	Darwish NS, Kim MA, Chang MS, Lee HS, Lee BL, Kim YI and Kim WH: Prognostic significance of CD24 expression in gastric carcinoma. Cancer Res Treat. 36:298–302. 2004. View Article : Google Scholar : PubMed/NCBI
19	Choi YL, Kim SH, Shin YK, Hong YC, Lee SJ, Kang SY and Ahn G: Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors. Gynecol Oncol. 97:379–386. 2005. View Article : Google Scholar : PubMed/NCBI
20	Smith SC, Oxford G, Wu Z, Nitz MD, Conaway M, Frierson HF, Hampton G and Theodorescu D: The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res. 66:1917–1922. 2006. View Article : Google Scholar : PubMed/NCBI
21	Bretz N, Noske A, Keller S, Erbe-Hofmann N, Schlange T, Salnikov AV, Moldenhauer G, Kristiansen G and Altevogt P: CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion. Clin Exp Metastasis. 29:27–38. 2012. View Article : Google Scholar : PubMed/NCBI
22	Baumann P, Cremers N, Kroese F, Orend G, Chiquet-Ehrismann R, Uede T, Yagita H and Sleeman JP: CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res. 65:10783–10793. 2005. View Article : Google Scholar : PubMed/NCBI
23	Aggarwal BB, Sundaram C, Malani N and Ichikawa H: Curcumin: The Indian solid gold. Adv Exp Med Biol. 595:1–75. 2007. View Article : Google Scholar : PubMed/NCBI
24	Labbozzetta M, Notarbartolo M, Poma P, Maurici A, Inguglia L, Marchetti P, Rizzi M, Baruchello R, Simoni D and D'Alessandro N: Curcumin as a possible lead compound against hormone-independent, multidrug-resistant breast cancer. Ann NY Acad Sci. 1155:278–283. 2009. View Article : Google Scholar : PubMed/NCBI
25	Calaf GM and Hei TK: Establishment of a radiation- and estrogen-induced breast cancer model. Carcinogenesis. 21:769–776. 2000. View Article : Google Scholar : PubMed/NCBI
26	Lakhani SR, Ellis IO, Schnitt SJ, Tan PH and van de Vijver MJ: WHO Classification of Tumors of the Breast. 4. 4th edition. International Agency for Research on Cancer; Lyon, France: 2012
27	Dontu G, Al-Hajj M, Abdallah WM, Clarke MF and Wicha MS: Stem cells in normal breast development and breast cancer. Cell Prolif. 36 Suppl 1:59–72. 2003. View Article : Google Scholar : PubMed/NCBI
28	Dontu G, El-Ashry D and Wicha MS: Breast cancer, stem/progenitor cells and the estrogen receptor. Trends Endocrinol Metab. 15:193–197. 2004. View Article : Google Scholar : PubMed/NCBI
29	Kordon EC and Smith GH: An entire functional mammary gland may comprise the progeny from a single cell. Development. 125:1921–1930. 1998.PubMed/NCBI
30	Ricardo S, Vieira AF, Gerhard R, Leitão D, Pinto R, Cameselle-Teijeiro JF, Milanezi F, Schmitt F and Paredes J: Breast cancer stem cell markers CD44, CD24 and ALDH1: Expression distribution within intrinsic molecular subtype. J Clin Pathol. 64:937–946. 2011. View Article : Google Scholar : PubMed/NCBI
31	Zhou L, Jiang Y, Yan T, Di G, Shen Z, Shao Z and Lu J: The prognostic role of cancer stem cells in breast cancer: A meta-analysis of published literatures. Breast Cancer Res Treat. 122:795–801. 2010. View Article : Google Scholar : PubMed/NCBI
32	Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ and Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
33	Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S and Nakshatri H: CD44⁺/CD24⁻ breast cancer cells exhibit enhanced invasive properties: An early step necessary for metastasis. Breast Cancer Res. 8:R592006. View Article : Google Scholar : PubMed/NCBI
34	Honeth G, Bendahl PO, Ringnér M, Saal LH, Gruvberger-Saal SK, Lövgren K, Grabau D, Fernö M, Borg A and Hegardt C: The CD44⁺/CD24⁻ phenotype Is enriched in basal-like breast tumors. Breast Cancer Res. 10:R532008. View Article : Google Scholar : PubMed/NCBI
35	Mylona E, Giannopoulou I, Fasomytakis E, Nomikos A, Magkou C, Bakarakos P and Nakopoulou L: The clinicopathologic and prognostic significance of CD44⁺/CD24^−/low and CD44⁻/CD24⁺ tumor cells in invasive breast carcinomas. Hum Pathol. 39:1096–1102. 2008. View Article : Google Scholar : PubMed/NCBI
36	Croker AK, Goodale D, Chu J, Postenka C, Hedley BD, Hess DA and Allan AL: High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med. 13:2236–2252. 2009. View Article : Google Scholar : PubMed/NCBI
37	Meyer MJ, Fleming JM, Ali MA, Pesesky MW, Ginsburg E and Vonderhaar BK: Dynamic regulation of CD24 and the invasive, CD44^posCD24^neg phenotype In breast cancer cell lines. Breast Cancer Res. 11:R822009. View Article : Google Scholar : PubMed/NCBI
38	Visvader JE and Lindeman GJ: Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer. 8:755–768. 2008. View Article : Google Scholar : PubMed/NCBI